niacinamide has been researched along with Gastrointestinal Stromal Neoplasm in 25 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluated the efficacy and safety of sorafenib in patients with advanced gastrointestinal stromal tumors (GIST) who failed to previous standard treatments." | 9.16 | Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. ( Im, SA; Kang, BY; Kang, YK; Kwon, HC; Lee, SS; Park, SH; Park, SR; Ryoo, BY; Ryu, MH, 2012) |
| " The aim of this single-arm phase II clinical study was to assess the efficacy and safety of single-agent motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate." | 9.14 | Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate. ( Baba, H; Doi, T; Kanda, T; Komatsu, Y; Koseki, M; Murakami, K; Nishida, T; Sawaki, A; Sun, YN; Yamada, Y, 2010) |
| "Sorafenib has substantial clinical activity as third- or fourth-line treatment of imatinib- and sunitinib-resistant gastrointestinal stromal tumors (GIST)." | 7.78 | Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. ( Donsky, RS; Fletcher, JA; Griffith, DJ; Heinrich, MC; Liang, CW; Marino-Enriquez, A; McKinley, A; Patterson, J; Presnell, A; Taguchi, T, 2012) |
| "To report a case of nephrotic syndrome (NS) induced by both sunitinib and sorafenib therapy." | 7.78 | Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor. ( Benekli, M; Buyukberber, S; Cetin, B; Guz, G; Inal, S; Memis, L; Ozturk, SC; Turan, N, 2012) |
| "To evaluated the efficacy and safety of sorafenib in patients with advanced gastrointestinal stromal tumors (GIST) who failed to previous standard treatments." | 5.16 | Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. ( Im, SA; Kang, BY; Kang, YK; Kwon, HC; Lee, SS; Park, SH; Park, SR; Ryoo, BY; Ryu, MH, 2012) |
| " The aim of this single-arm phase II clinical study was to assess the efficacy and safety of single-agent motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate." | 5.14 | Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate. ( Baba, H; Doi, T; Kanda, T; Komatsu, Y; Koseki, M; Murakami, K; Nishida, T; Sawaki, A; Sun, YN; Yamada, Y, 2010) |
| "Sorafenib has substantial clinical activity as third- or fourth-line treatment of imatinib- and sunitinib-resistant gastrointestinal stromal tumors (GIST)." | 3.78 | Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. ( Donsky, RS; Fletcher, JA; Griffith, DJ; Heinrich, MC; Liang, CW; Marino-Enriquez, A; McKinley, A; Patterson, J; Presnell, A; Taguchi, T, 2012) |
| "To report a case of nephrotic syndrome (NS) induced by both sunitinib and sorafenib therapy." | 3.78 | Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor. ( Benekli, M; Buyukberber, S; Cetin, B; Guz, G; Inal, S; Memis, L; Ozturk, SC; Turan, N, 2012) |
| "The multitargeted kinase inhibitors sorafenib and sunitinib have improved treatment of solid tumours including renal cell carcinoma and hepatocellular carcinoma by offering better clinical responses." | 3.75 | Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. ( Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC, 2009) |
| " The most common motesanib treatment-related grade 3 adverse events included hypertension (23%), fatigue (9%), and diarrhea (5%)." | 2.76 | Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. ( Baker, L; Benjamin, RS; Blay, JY; Bui, BN; Duyster, J; Hartmann, JT; McCoy, S; Reichardt, P; Rosen, LS; Schöffski, P; Schuetze, S; Skubitz, K; Stepan, DE; Sun, YN; Van Oosterom, A, 2011) |
| "Sorafenib was moderately tolerated, and toxicity reported in 56% of the patients." | 1.39 | Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. ( Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J, 2013) |
| "Scientific knowledge on gastrointestinal stromal tumors (GIST) has highly progressed over the last 10 years." | 1.38 | [KIT and KIT: from biology to clinical use]. ( Blay, JY; Chaigneau, L; Curtit, E; Dobi, E; Kalbacher, E; Mansi, L; Nguyen, T; Pivot, X; Viel, E, 2012) |
| "Sorafenib was potent against all imatinib-resistant Ba/F3 KIT double mutants tested, including the gatekeeper secondary mutation KIT(WK557-8del/T670I), which was resistant to other kinase inhibitors." | 1.34 | Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. ( Agaram, NP; Antonescu, CR; Besmer, P; Clarkson, BD; D'Adamo, D; DeMatteo, RP; Guo, T; Hom, G; Maki, RG; Schwartz, GK; Singer, S; Veach, D; Wong, GC, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (44.00) | 29.6817 |
| 2010's | 14 (56.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huynh, H | 1 |
| Lee, JW | 1 |
| Chow, PK | 1 |
| Ngo, VC | 1 |
| Lew, GB | 1 |
| Lam, IW | 1 |
| Ong, HS | 1 |
| Chung, A | 1 |
| Soo, KC | 1 |
| Lee, WJ | 1 |
| Lee, JL | 1 |
| Chang, SE | 1 |
| Lee, MW | 1 |
| Kang, YK | 2 |
| Choi, JH | 1 |
| Moon, KC | 1 |
| Koh, JK | 1 |
| Sawaki, A | 1 |
| Yamada, Y | 1 |
| Komatsu, Y | 1 |
| Kanda, T | 1 |
| Doi, T | 1 |
| Koseki, M | 1 |
| Baba, H | 1 |
| Sun, YN | 2 |
| Murakami, K | 1 |
| Nishida, T | 1 |
| Wang, ZY | 1 |
| Tardieu, M | 1 |
| Dômont, J | 1 |
| Cioffi, A | 2 |
| Bonvalot, S | 1 |
| Le Cesne, A | 2 |
| Caenepeel, S | 1 |
| Renshaw-Gegg, L | 1 |
| Baher, A | 1 |
| Bush, TL | 1 |
| Baron, W | 1 |
| Juan, T | 1 |
| Manoukian, R | 1 |
| Tasker, AS | 1 |
| Polverino, A | 1 |
| Hughes, PE | 1 |
| Benjamin, RS | 1 |
| Schöffski, P | 2 |
| Hartmann, JT | 1 |
| Van Oosterom, A | 1 |
| Bui, BN | 1 |
| Duyster, J | 1 |
| Schuetze, S | 1 |
| Blay, JY | 4 |
| Reichardt, P | 1 |
| Rosen, LS | 1 |
| Skubitz, K | 1 |
| McCoy, S | 1 |
| Stepan, DE | 1 |
| Baker, L | 1 |
| Pérez López, G | 1 |
| Carrasco De La Fuente, M | 1 |
| Menacho Román, M | 1 |
| González Albarrán, O | 1 |
| Cano Megías, M | 1 |
| Curtit, E | 1 |
| Mansi, L | 1 |
| Viel, E | 1 |
| Dobi, E | 1 |
| Chaigneau, L | 1 |
| Nguyen, T | 1 |
| Pivot, X | 1 |
| Kalbacher, E | 1 |
| Italiano, A | 3 |
| Coco, P | 1 |
| Maki, RG | 3 |
| Rutkowski, P | 2 |
| Duffaud, F | 2 |
| Adenis, A | 1 |
| Isambert, N | 1 |
| Bompas, E | 1 |
| Casali, P | 1 |
| Keohan, ML | 1 |
| Toulmonde, M | 1 |
| Antonescu, CR | 2 |
| Debiec-Rychter, M | 1 |
| Coindre, JM | 3 |
| Bui, B | 3 |
| Park, SH | 1 |
| Ryu, MH | 1 |
| Ryoo, BY | 1 |
| Im, SA | 1 |
| Kwon, HC | 1 |
| Lee, SS | 1 |
| Park, SR | 1 |
| Kang, BY | 1 |
| Roubaud, G | 1 |
| Kind, M | 1 |
| Jagannathan, JP | 1 |
| Ramaiya, NH | 1 |
| Shinagare, AB | 1 |
| Hornick, JL | 1 |
| George, S | 1 |
| Heinrich, MC | 1 |
| Marino-Enriquez, A | 1 |
| Presnell, A | 1 |
| Donsky, RS | 1 |
| Griffith, DJ | 1 |
| McKinley, A | 1 |
| Patterson, J | 1 |
| Taguchi, T | 1 |
| Liang, CW | 1 |
| Fletcher, JA | 1 |
| Turan, N | 1 |
| Benekli, M | 1 |
| Ozturk, SC | 1 |
| Inal, S | 1 |
| Memis, L | 1 |
| Guz, G | 1 |
| Cetin, B | 1 |
| Buyukberber, S | 1 |
| Montemurro, M | 1 |
| Gelderblom, H | 1 |
| Bitz, U | 1 |
| Schütte, J | 1 |
| Joensuu, H | 1 |
| Trent, J | 1 |
| Bauer, S | 1 |
| Pink, D | 1 |
| Le Jeune, S | 1 |
| Des Guetz, G | 1 |
| Bihan, H | 1 |
| Cohen, R | 1 |
| Mourad, JJ | 1 |
| Marx, J | 1 |
| King, CR | 1 |
| Blanke, C | 1 |
| von Mehren, M | 1 |
| Grabellus, F | 1 |
| Ebeling, P | 1 |
| Worm, K | 1 |
| Sheu, SY | 1 |
| Antoch, G | 1 |
| Frilling, A | 1 |
| Schmid, KW | 1 |
| Guo, T | 1 |
| Agaram, NP | 1 |
| Wong, GC | 1 |
| Hom, G | 1 |
| D'Adamo, D | 1 |
| Schwartz, GK | 1 |
| Veach, D | 1 |
| Clarkson, BD | 1 |
| Singer, S | 1 |
| DeMatteo, RP | 1 |
| Besmer, P | 1 |
| Apice, G | 1 |
| Milano, A | 1 |
| Bruni, GS | 1 |
| Iaffaioli, RV | 1 |
| Caponigro, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate[NCT00089960] | Phase 2 | 138 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| An Open-label Phase 2 Study of AMG 706 in Japanese Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate[NCT00254267] | Phase 2 | 35 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Phase II Study of Sorafenib in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors Who Failed to Imatinib and Sunitinib[NCT01091207] | Phase 2 | 39 participants (Anticipated) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for niacinamide and Gastrointestinal Stromal Neoplasm
| Article | Year |
|---|---|
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2009 |
[Focus on GIST management].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chemotherapy, Adjuvant; Drug Resistance, Neopl | 2010 |
Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Deliv | 2006 |
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevaci | 2006 |
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm | 2008 |
Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Dioxoles; Drug Resistance, Neoplasm; Gast | 2006 |
3 trials available for niacinamide and Gastrointestinal Stromal Neoplasm
| Article | Year |
|---|---|
Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Benzamides; Drug Resistance, Ne | 2010 |
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Fre | 2011 |
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Fre | 2011 |
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Fre | 2011 |
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Fre | 2011 |
Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Drug Resistance, Neoplasm; Female; Gastrointestina | 2012 |
16 other studies available for niacinamide and Gastrointestinal Stromal Neoplasm
| Article | Year |
|---|---|
Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Base Sequence; Benzenesulfonates; Body Weight; Disease Models, Anima | 2009 |
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfon | 2009 |
Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.
Topics: Animals; Blotting, Western; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Female; Gastroint | 2010 |
[Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
Topics: Adult; Benzamides; Benzenesulfonates; Carcinoma, Renal Cell; Choristoma; Female; Gastrointestinal St | 2011 |
[KIT and KIT: from biology to clinical use].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Gastrointestinal Stromal Tumors; Humans; Imati | 2012 |
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenes | 2012 |
Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series.
Topics: Antineoplastic Agents; Benzenesulfonates; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stroma | 2012 |
Intracranial metastasis from pediatric GI stromal tumor.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Brain Neo | 2012 |
Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.
Topics: Benzamides; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Stromal | 2012 |
Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Gastrointestinal Neoplasms; Gastrointestinal Str | 2012 |
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemothe | 2013 |
Refractory hypoglycemia controlled by sorafenib in solitary fibrous tumor.
Topics: Adult; Gastrointestinal Stromal Tumors; Humans; Hypoglycemia; Male; Niacinamide; Phenylurea Compound | 2013 |
Cancer. Encouraging results for second-generation antiangiogenesis drugs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2005 |
Current and future management of GIST.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Benzoquinones; Disease Progression; Dose-Respo | 2006 |
Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour.
Topics: Base Sequence; Benzamides; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gastrointes | 2007 |
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Proliferation; Dasati | 2007 |